Disc Medicine(IRON) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update • Presented top-line results from AURORA, the placebo-controlled phase 2 study of bitopertin in erythropoietic porphyrias (EPP), in April 2024 • On track to deliver additional analyses from BEACON and AURORA in Q2 2024 • Plan to present updated data from the phase 1b/2 study of DISC-0974 in anemia of myelofibrosis (MF), as well as initial single-ascending dose (SAD) data from the phase 1 study of DISC-3405 i ...